Registration gives the benefit of site update e-mails and additional information from Takeda on new education materials and events.
ADHD Institute Register
Home | Meetings & events » On-demand events » Webinar: Adult ADHD and comorbid anxiety disorders webinar

The 'Adult ADHD and comorbid anxiety disorders' webinar was hosted by Dr Mohamed Abdelghani (Dyad Medical, London, UK) on Monday 2 July. He was joined by a panel of experts from across the UK, Dr Joe Johnson, Dr Peter Mason and Dr Kuben Naidoo, for an interactive patient case study discussion.

These webinars may in part reflect the personal experiences and opinions of the presenters. Treatment-related statements do not necessarily reflect Takeda's position nor are they necessarily in line with the approved labels in all countries.


Question 1 (of 4)

In the Spanish CAT study, what percentage of adult patients with ADHD presented with one or more psychiatric comorbidity?

Please select one of the following

12.6%
35.5%
53.9%
66.2%

Question 2 (of 4)

What was the 12-month prevalence of any comorbid anxiety disorder in adults with ADHD in the US National Comorbidity Survey Replication?

Please select one of the following

13.6%
21.3%
35.4%
47.1%

Question 3 (of 4)

What was the 12-month prevalence of comorbid ADHD in adults with generalised anxiety disorder in the US National Comorbidity Survey Replication?

Please select one of the following

2.8%
11.9%
16.3%
21.2%

Question 4 (of 4)

In the Swedish population-based twin study by Friedrichs and colleagues (n=17,899; age 20–47 years), which ADHD subtype had the highest odds of comorbid generalised anxiety disorder?

Please mark all that apply

Combined type
Hyperactive-impulsive type
Inattentive type

Question 1 (of 4)

In the Spanish CAT study, what percentage of adult patients with ADHD presented with one or more psychiatric comorbidity?

Please select one of the following

12.6%
35.5%
53.9%
66.2%

Question 2 (of 4)

What was the 12-month prevalence of any comorbid anxiety disorder in adults with ADHD in the US National Comorbidity Survey Replication?

Please select one of the following

13.6%
21.3%
35.4%
47.1%

Question 3 (of 4)

What was the 12-month prevalence of comorbid ADHD in adults with generalised anxiety disorder in the US National Comorbidity Survey Replication?

Please select one of the following

2.8%
11.9%
16.3%
21.2%

Question 4 (of 4)

In the Swedish population-based twin study by Friedrichs and colleagues (n=17,899; age 20–47 years), which ADHD subtype had the highest odds of comorbid generalised anxiety disorder?

Please mark all that apply

Combined type
Hyperactive-impulsive type
Inattentive type

Date of preparation: March 2019; Job code: C-ANPROM/INT//3491

Filter content by:

Interactive module: Rating scale toolkit

An overview of rating scales used in the assessment of patients with ADHD

Interactive module: ADHD across the lifespan

ADHD Clinical Guidelines

View the videos from Meeting of Minds X, a scientific forum initiated, organised and funded by Shire, now part of Takeda

Registration

Healthcare professional registration

Registration gives the benefit of site update e-mails and additional information from Takeda on new education materials and events.

Persistence of ADHD from childhood to adulthood

Professor Sam Chang speaking at EUNETHYDIS 2018

Animation: Adult ADHD and the brain

An interactive guide to the MOA of selected medications used in the treatment of ADHD

Transition in ADHD

During transition from CAMHS to AMHS, adolescents may become lost in the system

eLearning module: Psychiatric comorbidities

eLearning module: Adult ADHD: burden and diagnosis

Interactive module: Understanding effect size

eLearning module: Treatment of child, adolescent and adult ADHD


ADHD Institue logo

You’re now being transferred to

and are leaving the ADHD Institute site

Takeda has no influence or control over the content of this third party website.

Continue Cancel